{
    "nct_id": "NCT04428788",
    "official_title": "A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer",
    "inclusion_criteria": "* Must have histologically or cytologically confirmed adenocarcinoma of the prostate\n* Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an androgen receptor (AR) degrader\n* Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP\n* Clinically significant venous thromboembolism within 3 months prior to the first dose of IP\n* Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}